Proteasome Inhibitors Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, Japan - Size and Forecast 2024-2028

Published: Dec 2023 Pages: 173 SKU: IRTNTR73564

Proteasome Inhibitors Market 2024-2028

The global proteasome inhibitors market size is estimated to grow by USD 2.91 billion at a CAGR of 7.48% between 2023 and 2028. 

Proteasome inhibition is a promising therapeutic approach for treating multiple myeloma. Cancer cells have higher levels of proteasome activity compared to normal cells, making them more sensitive to the proapoptotic effects of proteasome inhibition. Therefore, the proteasome is considered a therapeutic target in multiple myeloma. In addition, the limitations of existing therapies are driving the adoption rate of proteasome inhibitors. However, the recent approvals are showing impressive sales growth, which represents the continued strong adoption of proteasome inhibitors for the treatment of multiple myeloma. For instance, NINLARO from Takeda Pharmaceutical Co. Ltd. and KYPROLIS from Amgen Inc. registered an annual sales growth of around 18% and 7%, respectively, in 2021. Along with offsetting the impact of generic erosion on VELCADE, such strong sales growth also continues to drive growth for the market during the forecast period.

Technavio has segmented the market into Route Of Administration, Product, and Geography

  • The Route Of Administration segment is classified into oral and intravenous
  • The Product  segment is classified into Velcade, kyphosis, Ninlaro, and others
  • The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

What will be the Size of the Proteasome Inhibitors Market During the Forecast Period?

To learn more about this report, Download Report Sample

Proteasome Inhibitors Market Segmentation by Route Of Administration, Product and Geography Analysis

Route Of Administration Analysis

Oral

The market share growth by the oral segment will be significant during the forecast period. The oral segment of the global proteasome inhibitors market refers to the category of drugs that can be taken orally, usually in the form of tablets or capsules. These drugs are specifically designed to inhibit the activity of proteasomes, which are responsible for breaking down proteins in cells.

Get a glance at the market contribution of various segments Download PDF Sample

The oral segment was the largest and was valued at USD 4.00 billion in 2018. By inhibiting proteasomes, these drugs can interfere with the growth and survival of cancer cells, making them an important treatment option for various types of cancers. In recent years, the oral segment in the global proteasome inhibitors market has witnessed significant growth. This can be attributed to several factors. Firstly, the convenience and ease of administration of oral drugs make them more favored among patients when compared to intravenous or injectable alternatives. Further, ongoing advancements in research and development have led to the development of highly potent and selective oral proteasome inhibitors. These new drugs offer improved efficacy, reduced side effects, and better patient tolerance, thereby driving their adoption in clinical practice. Thus, the increased benefits of oral proteasome inhibitors will drive the growth of the oral segment of the global proteasome inhibitors market during the forecast period.

Product Analysis

Velcade

VELCADE is an intravenously administered first-generation proteasome inhibitor, which is a type of targeted therapy developed by Takeda Pharmaceutical Co. Ltd. (Takeda) and Johnson and Johnson. This drug inhibits the proteasome enzyme complex within the cell, which is a part of the cellular machinery. The drug also plays a major role in the regulation of cell division and cell survival. Inhibition of the proteasome enzyme complex leads to apoptosis of the disease-causing cell. VELCADE is the first proteasome inhibitor to receive marketing approval in major regions. Despite the companies receiving an extension on the patent rights of the drug until the end of 2022, the sales of VELCADE have witnessed a significant decline. Also, the heavy side effects associated with the treatment further act as a barrier to the growth of the segment. As a result, the segment is expected to lose a significant share and is expected to be the slowest-growing segment of the proteasome inhibitors market during the forecast period.

Kyprolis

KYPROLIS is a carfilzomib (a modified form of tetrapeptide epoxyketone)-based drug. It is a second-generation proteasome inhibitor, which is administered intravenously. It works by inhibiting the tetrapeptide epoxyketone proteasome by binding to the N-terminal threonine-containing active sites of the 20S proteasome. However, to reduce the cost burden on the patients, Amgen Inc. (Amgen) launched a patient assistance program called the Amgen Assist 360 in May 2021, which offers cost benefits such as co-pays and reimbursements. These reimbursement programs are expected to attract and encourage patients with multiple myeloma to undergo treatment using KYPROLIS. Owing to these factors, KYPROLIS is expected to witness high growth globally during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America is expected to benefit significantly from the heavy sales of approved proteasome inhibitors in the region for the treatment of various indications. Currently, three branded proteasome inhibitors and one generic proteasome inhibitor are approved in the region. The patent expiry of the blockbuster drug VELCADE has resulted in the development of generic versions of the drug by various large and mid-sized pharmaceutical vendors in the region. Currently, five vendors in the market are developing the generic version of VELCADE, with large vendors already operating in the market, while Allergan generic is being registered for the treatment of multiple myeloma.

However, despite the decrease in the number of new cases of non-Hodgkin lymphoma, the overall prevalence of the indication in the region is still very high. For instance, non-Hodgkin lymphoma is currently the seventh most prevalent cancer type in the US and is also the sixth most fatal type of cancer in the country. This is resulting in a huge unmet need in the region for advanced therapeutics for the treatment. The market is expected to benefit significantly from the increasing advances in the research of proteasome inhibitors in the forecast period.

Buy the Full Report Now

Key Proteasome Inhibitors Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Amgen Inc. - The company offer KYPROLIS proteasome inhibitor based on phase 3 ASPIRE trail to help patients reduce the risk of death over lenalidomide and dexamethasone.

  • Baxter International Inc.
  • Bio Techne Corp.
  • Bristol Myers Squibb Co.
  • Fresenius SE and Co. KGaA
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Kezar Life Sciences Inc.
  • LifeSensors Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • QLi5 Therapeutics
  • Takeda Pharmaceutical Co. Ltd.
  • TG Therapeutics Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Proteasome Inhibitors Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Proteasome Inhibitors Market Drivers

The huge unmet need for certain cancer therapeutics is notably driving the market growth. Currently, there are only a limited number of approved therapies for multiple myeloma, with three branded proteasome inhibitors and one generic proteasome inhibitor approved. This is primarily because pharmaceutical vendors are more focused on developing therapeutics for more common types of blood cancers, such as leukemia and lymphomas. Also, the complex pathogenesis of myeloma makes it difficult to develop therapeutics for the treatment. Although multiple myeloma is a less common type of blood cancer, the overall prevalence of the indication is still high. For instance, the market also has a very limited number of therapies approved for the treatment of pancreatic cancer.

Moreover, the market witnesses the presence of various vendors developing proteasome inhibitors in the late stages of clinical trials for multiple myeloma and two drugs for pancreatic cancer. The unmet need is expected to attract various large and mid-sized pharmaceutical vendors to conduct studies and launch the product, which is expected to help the market grow significantly during the forecast period.

Significant Proteasome Inhibitors Market Trends

High market growth potential in developing economies is an emerging trend shaping market growth. The rising demand for advanced therapeutic procedures for treating people diagnosed with cancer, the growing number of research institutes and speciality cancer hospitals, and rising healthcare spending are the major factors encouraging global as well as regional vendors to expand their footprint to developing countries, such as China and India.  The healthcare industry, which includes hospitals, clinics, research institutes, and speciality cancer treatment centers, is growing at a significant pace in these economies due to the rise in healthcare expenditure.

Additionally, the increase in the number of large- and mid-sized public and private hospitals providing cancer treatment in developing economies is also augmenting the demand for several advanced therapeutic procedures for treating multiple myeloma cancer patients and proteasome inhibitors for treatment. Hence, the increasing number of end-users providing multiple myeloma cancer treatment is expected to propel the growth of the global proteasome inhibitors market during the forecast period.

Major Proteasome Inhibitors Market Challenges

The slow regulatory approval process for proteasome inhibitors is a significant challenge hindering market growth. While the market has only three approved drugs, it has already witnessed the patent expiry of the major drug, VELCADE. This has resulted in the launch of a generic version of the drug, and various generics are being developed in the late stages of clinical trials. For instance, Fresenius Kabi AG (a subsidiary of Fresenius SE and Co. KGaA) developed MYLOSOME, a generic version of bortezomib, for the treatment of mantle cell lymphoma and multiple myeloma.

Moreover, the pharmaceutical industry is adopting new technologies to reduce the cost of production to provide cheaper therapeutics like generics to needy people in low- and middle-income countries. As a result, the regulatory bodies are approving the generics over the branded drugs. The increasing number of generics is expected to result in the value erosion of the market during the forecast period.

Buy Now Full Report

Key Proteasome Inhibitors Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Proteasome Inhibitors Market Customer Landscape

Segment Overview

The proteasome inhibitors market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  • Route Of Administration Outlook
    • Oral
    • Intravenous
  • Product Outlook
    • VELCADE
    • KYPROLIS
    • NINLARO
    • Others
  • Region Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW)
      • Brazil
      • Argentina 
      • Australia

Proteasome Inhibitors Market Scope

Report Coverage

Details

Page number

173

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 7.48%

Market Growth 2024-2028

USD 2.91 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

6.6

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 43%

Key countries

US, Canada, UK, Germany, and Japan

Competitive landscape

Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

Amgen Inc., Baxter International Inc., Bio Techne Corp., Bristol Myers Squibb Co., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Johnson and Johnson, Kezar Life Sciences Inc., LifeSensors Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., QLi5 Therapeutics, Takeda Pharmaceutical Co. Ltd., TG Therapeutics Inc., and Thermo Fisher Scientific Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. 

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Proteasome Inhibitors Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the proteasome inhibitors market between 2024 and 2028
  • Precise estimation of the proteasome inhibitors market size and its contribution to the market in focus to the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies' position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of proteasome inhibitors market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

 

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global proteasome inhibitors market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global proteasome inhibitors market 2018 - 2022 ($ billion)
    • 4.2 Route Of Administration Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Route Of Administration Segment 2018 - 2022 ($ billion)
    • 4.3 Product Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Product Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Route of Administration

    • 6.1 Market segments
      • Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)
    • 6.2 Comparison by Route of Administration
      • Exhibit 32: Chart on Comparison by Route of Administration
      • Exhibit 33: Data Table on Comparison by Route of Administration
    • 6.3 Oral - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
    • 6.4 Intravenous - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Intravenous - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Intravenous - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Intravenous - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Intravenous - Year-over-year growth 2023-2028 (%)
    • 6.5 Market opportunity by Route of Administration
      • Exhibit 42: Market opportunity by Route of Administration ($ billion)
      • Exhibit 43: Data Table on Market opportunity by Route of Administration ($ billion)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Exhibit 44: Chart on Product - Market share 2023-2028 (%)
      • Exhibit 45: Data Table on Product - Market share 2023-2028 (%)
    • 7.2 Comparison by Product
      • Exhibit 46: Chart on Comparison by Product
      • Exhibit 47: Data Table on Comparison by Product
    • 7.3 VELCADE - Market size and forecast 2023-2028
      • Exhibit 48: Chart on VELCADE - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 49: Data Table on VELCADE - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 50: Chart on VELCADE - Year-over-year growth 2023-2028 (%)
      • Exhibit 51: Data Table on VELCADE - Year-over-year growth 2023-2028 (%)
    • 7.4 KYPROLIS - Market size and forecast 2023-2028
      • Exhibit 52: Chart on KYPROLIS - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 53: Data Table on KYPROLIS - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 54: Chart on KYPROLIS - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on KYPROLIS - Year-over-year growth 2023-2028 (%)
    • 7.5 NINLARO - Market size and forecast 2023-2028
      • Exhibit 56: Chart on NINLARO - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 57: Data Table on NINLARO - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 58: Chart on NINLARO - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on NINLARO - Year-over-year growth 2023-2028 (%)
    • 7.6 Others - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 7.7 Market opportunity by Product
      • Exhibit 64: Market opportunity by Product ($ billion)
      • Exhibit 65: Data Table on Market opportunity by Product ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Japan - Market size and forecast 2023-2028
      • Exhibit 91: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on Japan - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on Japan - Year-over-year growth 2023-2028 (%)
    • 9.9 UK - Market size and forecast 2023-2028
      • Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.10 Canada - Market size and forecast 2023-2028
      • Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
    • 9.11 Germany - Market size and forecast 2023-2028
      • Exhibit 103: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 104: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 105: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ billion)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 Amgen Inc.
              • Exhibit 115: Amgen Inc. - Overview
              • Exhibit 116: Amgen Inc. - Product / Service
              • Exhibit 117: Amgen Inc. - Key offerings
            • 12.4 Baxter International Inc.
              • Exhibit 118: Baxter International Inc. - Overview
              • Exhibit 119: Baxter International Inc. - Business segments
              • Exhibit 120: Baxter International Inc. - Key news
              • Exhibit 121: Baxter International Inc. - Key offerings
              • Exhibit 122: Baxter International Inc. - Segment focus
            • 12.5 Bio Techne Corp.
              • Exhibit 123: Bio Techne Corp. - Overview
              • Exhibit 124: Bio Techne Corp. - Business segments
              • Exhibit 125: Bio Techne Corp. - Key offerings
              • Exhibit 126: Bio Techne Corp. - Segment focus
            • 12.6 Bristol Myers Squibb Co.
              • Exhibit 127: Bristol Myers Squibb Co. - Overview
              • Exhibit 128: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 129: Bristol Myers Squibb Co. - Key news
              • Exhibit 130: Bristol Myers Squibb Co. - Key offerings
            • 12.7 Fresenius SE and Co. KGaA
              • Exhibit 131: Fresenius SE and Co. KGaA - Overview
              • Exhibit 132: Fresenius SE and Co. KGaA - Business segments
              • Exhibit 133: Fresenius SE and Co. KGaA - Key news
              • Exhibit 134: Fresenius SE and Co. KGaA - Key offerings
              • Exhibit 135: Fresenius SE and Co. KGaA - Segment focus
            • 12.8 Johnson and Johnson
              • Exhibit 136: Johnson and Johnson - Overview
              • Exhibit 137: Johnson and Johnson - Business segments
              • Exhibit 138: Johnson and Johnson - Key news
              • Exhibit 139: Johnson and Johnson - Key offerings
              • Exhibit 140: Johnson and Johnson - Segment focus
            • 12.9 Kezar Life Sciences Inc.
              • Exhibit 141: Kezar Life Sciences Inc. - Overview
              • Exhibit 142: Kezar Life Sciences Inc. - Product / Service
              • Exhibit 143: Kezar Life Sciences Inc. - Key news
              • Exhibit 144: Kezar Life Sciences Inc. - Key offerings
            • 12.10 LifeSensors Inc.
              • Exhibit 145: LifeSensors Inc. - Overview
              • Exhibit 146: LifeSensors Inc. - Product / Service
              • Exhibit 147: LifeSensors Inc. - Key offerings
            • 12.11 Merck and Co. Inc.
              • Exhibit 148: Merck and Co. Inc. - Overview
              • Exhibit 149: Merck and Co. Inc. - Business segments
              • Exhibit 150: Merck and Co. Inc. - Key news
              • Exhibit 151: Merck and Co. Inc. - Key offerings
              • Exhibit 152: Merck and Co. Inc. - Segment focus
            • 12.12 Novartis AG
              • Exhibit 153: Novartis AG - Overview
              • Exhibit 154: Novartis AG - Business segments
              • Exhibit 155: Novartis AG - Key offerings
              • Exhibit 156: Novartis AG - Segment focus
            • 12.13 Pfizer Inc.
              • Exhibit 157: Pfizer Inc. - Overview
              • Exhibit 158: Pfizer Inc. - Product / Service
              • Exhibit 159: Pfizer Inc. - Key news
              • Exhibit 160: Pfizer Inc. - Key offerings
            • 12.14 QLi5 Therapeutics
              • Exhibit 161: QLi5 Therapeutics - Overview
              • Exhibit 162: QLi5 Therapeutics - Product / Service
              • Exhibit 163: QLi5 Therapeutics - Key offerings
            • 12.15 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 164: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 165: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Key offerings
            • 12.16 TG Therapeutics Inc.
              • Exhibit 168: TG Therapeutics Inc. - Overview
              • Exhibit 169: TG Therapeutics Inc. - Product / Service
              • Exhibit 170: TG Therapeutics Inc. - Key offerings
            • 12.17 Thermo Fisher Scientific Inc.
              • Exhibit 171: Thermo Fisher Scientific Inc. - Overview
              • Exhibit 172: Thermo Fisher Scientific Inc. - Business segments
              • Exhibit 173: Thermo Fisher Scientific Inc. - Key news
              • Exhibit 174: Thermo Fisher Scientific Inc. - Key offerings
              • Exhibit 175: Thermo Fisher Scientific Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 176: Inclusions checklist
                • Exhibit 177: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 178: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 179: Research methodology
                • Exhibit 180: Validation techniques employed for market sizing
                • Exhibit 181: Information sources
              • 13.5 List of abbreviations
                • Exhibit 182: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              proteasome inhibitors market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis